Effect of adding samen-ista powder in controlling bleeding

Study of the effect of adding samen-ista powder in controlling bleeding of superficial scalp injuries in patients referred to the emergency department

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210703051771N1

Enrollment

Registered

2021-09-12

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open wound of the unspecified body region.. Unspecified injury

Interventions

Intervention 1: Intervention Group: The intervention group will receive Samen Ista medicine, which is a 4-gram vial. The white powder is first dissolved in 25 CC of distilled water and then poured on

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age of >18 years Informed consent to participate in the study Active bleeding and consistent vital signs

Exclusion criteria

Exclusion criteria: Having underlying coagulation diseases Use of anticoagulants Arterial bleeding Need for additional treatment Age of >65 years Injuries with burns (electrical, thermal, chemical burns) or crushes Having active inflammatory lesions Neoplasm Presence of active infectious lesions (bacterial, fungal, viral, or parasitic) Recent surgery on the scalp (within two weeks) or hair transplant in the last 3 months Renal failure (ESRD) Pregnancy

Design outcomes

Primary

Measure	Time frame
Injury dimensions (1-12 cm). Timepoint: It will be carried out in a 1-day period, the wound will be examined for homeostasis, and the time required for homeostasis will be recorded. Method of measurement: Measurement of Injury dimensions.;Scalp injury location. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: Measurement of Injury dimensions.;Duration of active bleeding. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: According to the duration of active bleeding.;Re-perfusion. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: Re-perfusion.;Duration of homeostasis. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: According to the duration of homeostasis.	—

Measure

Time frame

Injury dimensions (1-12 cm). Timepoint: It will be carried out in a 1-day period, the wound will be examined for homeostasis, and the time required for homeostasis will be recorded. Method of measurement: Measurement of Injury dimensions.;Scalp injury location. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: Measurement of Injury dimensions.;Duration of active bleeding. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: According to the duration of active bleeding.;Re-perfusion. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: Re-perfusion.;Duration of homeostasis. Timepoint: It will be carried out in a 1-day period, the wound will be examined for hemostasis, and the time required for homeostasis will be recorded. Method of measurement: According to the duration of homeostasis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamideh Feiz Disfani

Mashhad University of Medical Sciences

feyzh@mums.ac.ir+98 51 3273 7015

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026